129 related articles for article (PubMed ID: 32527129)
21. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
[TBL] [Abstract][Full Text] [Related]
22. Malignant effusions from extranodal NK/T-cell lymphomas are frequently of anaplastic morphology with azurophilic granules and of T-cell lineage.
Liu CY; Chen BJ; Chuang SS;
Diagn Cytopathol; 2020 May; 48(5):453-463. PubMed ID: 32020785
[TBL] [Abstract][Full Text] [Related]
23. Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.
Mundy-Bosse BL; Weigel C; Wu YZ; Abdelbaky S; Youssef Y; Casas SB; Polley N; Ernst G; Young KA; McConnell KK; Nalin AP; Wu KG; Broughton M; Lordo MR; Altynova E; Hegewisch-Solloa E; Enriquez-Vera DY; Dueñas D; Barrionuevo C; Yu SC; Saleem A; Suarez CJ; Briercheck EL; Molina-Kirsch H; Loughran TP; Weichenhan D; Plass C; Reneau JC; Mace EM; Gamboa FV; Weinstock DM; Natkunam Y; Caligiuri MA; Mishra A; Porcu P; Baiocchi RA; Brammer JE; Freud AG; Oakes CC
Blood Cancer Discov; 2022 Mar; 3(2):154-169. PubMed ID: 35247900
[TBL] [Abstract][Full Text] [Related]
24. A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment.
Chen Z; Fang X; Huang H; Wang Z; Hong H; Chen M; Ren Q; Yao Y; Zhang L; Tian Y; Lin S; Lin T
Ann Hematol; 2020 Dec; 99(12):2811-2819. PubMed ID: 32975588
[TBL] [Abstract][Full Text] [Related]
25. Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma Recurrence at Penile Glans Masquerading Urinary Contamination on 18 F-FDG PET/CT.
Zhang Y; Yu L; Wang R; Su M
Clin Nucl Med; 2023 Sep; 48(9):812-814. PubMed ID: 37418289
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang H; Jiang Y; Yang Q; Xie L; Liu W; Zhang W; Ji X; Li P; Chen N; Zhao S; Wang F; Zou L
Cancer; 2012 Jul; 118(13):3294-301. PubMed ID: 22139825
[TBL] [Abstract][Full Text] [Related]
27. Dynamic evaluation of the prognostic value of
Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
[TBL] [Abstract][Full Text] [Related]
28. Progress of Hematopoietic Stem Cell Transplantation and Radiotherapy in the Treatment of Extranodal NK/T Cell Lymphoma.
Terro K; Sharrouf L; El Cheikh J
Front Oncol; 2022; 12():832428. PubMed ID: 35252002
[TBL] [Abstract][Full Text] [Related]
29. Extranodal natural killer/T-cell lymphoma, nasal type: a Spanish multicentric retrospective survey.
Rozas-Muñoz E; Gallardo F; Pujol RM; Pérez-Ferriols A; Servitje O; Estrach T; Bastida J; Román C; Palacio-Aller L; Gil I; Martí RM; Vidal-Sarró D; García-Muret MP
Eur J Dermatol; 2018 Feb; 28(1):64-70. PubMed ID: 29400283
[TBL] [Abstract][Full Text] [Related]
30. Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study.
Mei M; Wang Y; Zhang M
PLoS One; 2019; 14(4):e0214860. PubMed ID: 30995261
[TBL] [Abstract][Full Text] [Related]
31. Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.
Wang H; Li P; Zhang X; Xia Z; Lu Y; Huang H
Oncol Lett; 2016 Aug; 12(2):825-836. PubMed ID: 27446357
[TBL] [Abstract][Full Text] [Related]
32. Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I
Wang HY; Niu SQ; Yang YY; Li YY; Chen HB; Zhang YJ
Cancer Med; 2018 Dec; 7(12):5863-5869. PubMed ID: 30484966
[TBL] [Abstract][Full Text] [Related]
33. Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability.
Kim SM; Park S; Oh DR; Ahn YC; Ko YH; Kim SJ; Kim WS
Ann Hematol; 2016 Mar; 95(4):581-91. PubMed ID: 26729202
[TBL] [Abstract][Full Text] [Related]
34. Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.
Xu Y; Wang J; Zhang W; Liu J; Cao X; He A; Chen Y; Gu L; Lei B; Zhang P; Ma X
Med Sci Monit; 2016 Nov; 22():4297-4311. PubMed ID: 27843135
[TBL] [Abstract][Full Text] [Related]
35. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
Fox CP; Civallero M; Ko YH; Manni M; Skrypets T; Pileri S; Kim SJ; Cabrera ME; Shustov AR; Chiattone CS; Horwitz SM; Dlouhy I; Spina M; Hitz F; Montoto S; Nagler A; Martinez V; De Souza CA; Fernandez-Alvarez R; Ballova V; Gabús R; Inghirami G; Federico M; Kim WS
Lancet Haematol; 2020 Apr; 7(4):e284-e294. PubMed ID: 32105608
[TBL] [Abstract][Full Text] [Related]
36. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas.
Dubal PM; Dutta R; Vazquez A; Patel TD; Baredes S; Eloy JA
Laryngoscope; 2015 May; 125(5):1077-83. PubMed ID: 25546466
[TBL] [Abstract][Full Text] [Related]
37. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
38. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
39. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.
Du L; Zhang L; Li L; Li X; Yan J; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Onco Targets Ther; 2020; 13():7189-7197. PubMed ID: 32801749
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
